Cargando…

Do intravitreal anti-vascular endothelial growth factor agents lead to renal adverse events? A pharmacovigilance real-world study

PURPOSE: Intravitreal vascular endothelial growth factor (VEGF) blockade is essential in many macular edema diseases treatment. However, intravitreal VEGF treatment has been reported to lead to deteriorated proteinuria and renal function. This study aimed to explore the relationship between renal ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jiang, Lin, Peng, Liying, Zhou, Yangzhong, Chen, Gang, Zhao, Bin, Li, Mingxi, Li, Xuemei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9972674/ https://www.ncbi.nlm.nih.gov/pubmed/36865057 http://dx.doi.org/10.3389/fmed.2023.1100397

Ejemplares similares

Pharmacovigilance of triazole antifungal agents: Analysis of the FDA adverse event reporting system (FAERS) database
por: Zhou, Jianxing, et al.
Publicado: (2022)

Association between Obstetric Complications and Intravitreal Anti-Vascular Endothelial Growth Factor Agents or Intravitreal Corticosteroids
por: Ben Ghezala, Inès, et al.
Publicado: (2022)

Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2023)

Adverse events with intravitreal injection of vascular endothelial growth factor inhibitors: nested case-control study
por: Campbell, Robert J, et al.
Publicado: (2012)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for osimertinib
por: Yin, Yanchao, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib
por: Guo, Menglin, et al.
Publicado: (2022)

A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for venetoclax
por: Yang, Yang, et al.
Publicado: (2022)

Intravitreal Anti Vascular Endothelial Growth Factor Agents in The Management of Retinal Diseases: An Audit
por: Fiebai, Bassey, et al.
Publicado: (2017)

Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study
por: Zhao, Bin, et al.
Publicado: (2021)

A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib
por: Wu, Yan, et al.
Publicado: (2023)

Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents for Ocular Vascular Diseases: Clinical Practice Guideline
por: Nikkhah, Homayoun, et al.
Publicado: (2018)

Severe cutaneous adverse reactions to drugs: A real-world pharmacovigilance study using the FDA Adverse Event Reporting System database
por: Li, Dongxuan, et al.
Publicado: (2023)

Intravitreal anti-vascular endothelial growth factor agents as an adjunct in the management of coats' disease in children
por: Kaul, Shalini, et al.
Publicado: (2010)

Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents
por: Ruão, Miguel, et al.
Publicado: (2017)

Causative Pathogens in Endophthalmitis after Intravitreal Injection of Anti-vascular Endothelial Growth Factor Agents
por: Labardini, Cecilia P., et al.
Publicado: (2018)

Intravitreal Anti-Vascular Endothelial Growth Factor Agents for the Treatment of Diabetic Retinopathy: A Review of the Literature
por: Chatziralli, Irini, et al.
Publicado: (2021)

Adverse drug event presentation and tracking (ADEPT): semiautomated, high throughput pharmacovigilance using real-world data
por: Geva, Alon, et al.
Publicado: (2020)

Adverse Event Profile Differences between Trastuzumab Emtansine and Trastuzumab Deruxtecan: A Real-world, Pharmacovigilance Study
por: Liu, Fen, et al.
Publicado: (2023)

Pharmacovigilance on cannabidiol as an antiepileptic agent
por: Ammendolia, Ilaria, et al.
Publicado: (2023)

Intraocular Pressure Changes in Non-Glaucomatous Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Agents
por: Kiddee, Weerawat, et al.
Publicado: (2015)

Adverse Events Associated with Nirmatrelvir/Ritonavir: A Pharmacovigilance Analysis Based on FAERS
por: Li, Meng, et al.
Publicado: (2022)

Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System
por: Okada, Naoto, et al.
Publicado: (2023)

Acute kidney injury after COVID-19 vaccines: a real-world study
por: Luo, Huiting, et al.
Publicado: (2022)

Pharmacovigilance and drug safety 2011 in Calabria (Italy): Adverse events analysis
por: Scicchitano, Francesca, et al.
Publicado: (2012)

Pharmacovigilance and drug safety in Calabria (Italy): 2012 adverse events analysis
por: Giofrè, Chiara, et al.
Publicado: (2013)

Innovation in Pharmacovigilance: Use of Artificial Intelligence in Adverse Event Case Processing
por: Schmider, Juergen, et al.
Publicado: (2018)

Pharmacovigilance of Biopharmaceuticals in Rheumatic Diseases, Adverse Events, Evolution, and Perspective: An Overview
por: Rodríguez, Sandra, et al.
Publicado: (2020)

Pharmacovigilance in practice: erythropoiesis-stimulating agents
por: Hedenus, Michael, et al.
Publicado: (2014)

Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system
por: Shu, Yamin, et al.
Publicado: (2022)

Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders
por: Hang, Abraham, et al.
Publicado: (2023)

A pharmacovigilance study of etoposide in the FDA adverse event reporting system (FAERS) database, what does the real world say?
por: Cui, Zhiwei, et al.
Publicado: (2023)

Musculoskeletal adverse events induced by immune checkpoint inhibitors: a large-scale pharmacovigilance study
por: Liu, Hao, et al.
Publicado: (2023)

COVID-19 mRNA Vaccines Are Generally Safe in the Short Term: A Vaccine Vigilance Real-World Study Says
por: Chen, Gang, et al.
Publicado: (2021)

Safety of Antiplatelet Agents: Analysis of ‘Real-World’ Data from the Italian National Pharmacovigilance Network
por: Gozzo, Lucia, et al.
Publicado: (2017)

Does HIF-PHI increased risk of gastrointestinal hemorrhage in patients with renal anemia: a review of cases reported to the U.S. Food and drug administration adverse event reporting system
por: Zhou, Yangzhong, et al.
Publicado: (2021)

Fatal Events Associated with Adverse Drug Reactions in the Korean National Pharmacovigilance Database
por: Jo, Hyeong-Geun, et al.
Publicado: (2021)

Major adverse cardiovascular events associated with testosterone treatment: a pharmacovigilance study of the FAERS database
por: Zhao, Hui, et al.
Publicado: (2023)

Reduced Size of Telangiectatic Capillaries After Intravitreal Injection of Anti-Vascular Endothelial Growth Factor Agents in Diabetic Macular Edema
por: Itou, Junichi, et al.
Publicado: (2023)

Effect of Intravitreal Anti-Vascular Endothelial Growth Factor Therapy on the Risk of Arterial Thromboembolic Events: A Meta-Analysis
por: Cheng, Jin-Wei, et al.
Publicado: (2012)

Effect of repeated intravitreal anti-vascular endothelial growth factor drugs on corneal nerves
por: Qi, Yuanyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6rb6m58hhp3pm5b7dfk0o4oipr